This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on ISI (8)  • Contact me when this article is cited  Related Content  • Similar articles in this journal

Arch Ophthalmol. 1998;116:1115-1116.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Latanoprost, a 17-phenyl–substituted analog of PGF₂ , has been shown to effectively lower intraocular pressure in clinical trials and darken the irides in both subhuman primates and humans.¹ The reported time of onset of the change in iris color has been noted to be as early as 3 months. To our knowledge, this case represents the earliest reported change in iris color following the initiation of latanoprost use.

Report of a Case

A 78-year-old white woman was first seen in 1986 complaining of worsening vision, which was found to be secondary to nuclear sclerosis involving her right eye. She underwent an uncomplicated extracapsular cataract extraction with intraocular lens implantation in December 1988. Prior to surgery, she had intraocular pressure in the midteens and small symmetric cups with healthy neuroretinal rims. In 1992, she had elevated intraocular pressure in the right eye in the high 20s to low 30s. On visual field testing, she demonstrated . . . [Full Text of this Article]

Comment
Reprints: Eve J. Higginbotham, MD, Department of Ophthalmology, University of Maryland School of Medicine, 22 S Greene St, Baltimore, MD 21201.